Last reviewed · How we verify

NCT06867874: PAS

Syncytiotrophoblast-derived Extracellular Vesicles in Placenta Previa and Accreta Spectrum

Recruiting now NA Last updated 10 March 2025
What this trial tests

NA trial testing Blood sample in Placenta Previa in 70 participants. Currently enrolling.

Timeline
10 July 2023
Primary endpoint
1 March 2025
1 March 2026

Quick facts

Lead sponsorFondazione Policlinico Universitario Agostino Gemelli IRCCS
PhaseNA
StatusRecruiting now
Study typeINTERVENTIONAL
Allocationna
Designsingle group
Maskingnone
Primary purposebasic science
Enrollment70
Start date10 July 2023
Primary completion1 March 2025
Estimated completion1 March 2026
Sites1 location across Italy

Drugs / interventions tested

Conditions studied

Sponsor

Fondazione Policlinico Universitario Agostino Gemelli IRCCS

Who can join

18 and older, female only, with Placenta Previa or Placenta Accreta Spectrum. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The main goal of this case-control study is to quantify the levels of circulating syncytiotrophoblast-derived extracellular vesicles (STBEVs) in maternal blood in a population of women with placenta previa and placenta accreta spectrum.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Blood sample

Trials testing the same drug.

Other recruiting trials for Placenta Previa

Currently open trials in the same condition.

Other Fondazione Policlinico Universitario Agostino Gemelli IRCCS trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06867874.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing